

*Our estimate of the consolidated profit for the year ended December 31, 2020 is set out in “Financial information — Profit estimate for the year ended December 31, 2020” of this prospectus.*

**(A) BASES**

Our Directors have prepared the estimate of the consolidated profit attributable to owners of the Company for the year ended December 31, 2020 (the “Profit Estimate”) based on the audited consolidated results of our Group for the nine months ended September 30, 2020 and the unaudited consolidated results based on the management accounts of our Group for three months ended December 31, 2020. The Profit Estimate has been prepared on the basis of the accounting policies consistent in all material aspects with those currently adopted by our Group as summarized in the Accountant’s Report, the text of which is set out in Appendix I to this prospectus.

**(B) LETTER FROM THE REPORTING ACCOUNTANT**

*The following is the text of a letter received from PricewaterhouseCoopers, Certified Public Accountants, Hong Kong, for the purpose of incorporation in this prospectus.*



羅兵咸永道

The Board of Directors  
SciClone Pharmaceuticals (Holdings) Limited

Morgan Stanley Asia Limited  
China International Capital Corporation Hong Kong Securities Limited  
Credit Suisse (Hong Kong) Limited

February 19, 2021

Dear Sirs,  
SciClone Pharmaceuticals (Holdings) Limited (the “Company”)

**Profit Estimate for Year Ended December 31, 2020**

We refer to the estimate of the consolidated profit attributable to owners of the Company for the year ended December 31, 2020 (the “Profit Estimate”) set forth in the section headed “Profit Estimate for the Year Ended December 31, 2020” in the prospectus of the Company dated February 19, 2021 (the “Prospectus”).

**Directors’ Responsibilities**

The Profit Estimate has been prepared by the directors of the Company based on the audited consolidated results of the Company and its subsidiaries (collectively referred to as the “Group”) for the nine months ended September 30, 2020 and the unaudited consolidated results based on the management accounts of the Group for the three months ended December 31, 2020.

The Company’s directors are solely responsible for the Profit Estimate.

**Our Independence and Quality Control**

We have complied with the independence and other ethical requirements of the Code of Ethics for Professional Accountants issued by the Hong Kong Institute of Certified Public Accountants (“HKICPA”), which is founded on fundamental principles of integrity, objectivity, professional competence and due care, confidentiality and professional behavior.

Our firm applies Hong Kong Standard on Quality Control 1 issued by the HKICPA and accordingly maintains a comprehensive system of quality control including documented policies and procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.

---

*PricewaterhouseCoopers, 22/F Prince’s Building, Central, Hong Kong*  
T: +852 2289 8888, F: +852 2810 9888, www.pwchk.com

**Reporting Accountant’s Responsibilities**

Our responsibility is to express an opinion on the accounting policies and calculations of the Profit Estimate based on our procedures.

We conducted our engagement in accordance with Hong Kong Standard on Investment Circular Reporting Engagements 500 “Reporting on Profit Forecasts, Statements of Sufficiency of Working Capital and Statements of Indebtedness” and with reference to Hong Kong Standard on Assurance Engagements 3000 (Revised) “Assurance Engagements Other Than Audits or Reviews of Historical Financial Information” issued by the HKICPA. Those standards require that we plan and perform our work to obtain reasonable assurance as to whether, so far as the accounting policies and calculations are concerned, the Company’s directors have properly compiled the Profit Estimate in accordance with the bases adopted by the directors and as to whether the Profit Estimate is presented on a basis consistent in all material respects with the accounting policies normally adopted by the Group. Our work is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing issued by the HKICPA. Accordingly, we do not express an audit opinion.

**Opinion**

In our opinion, so far as the accounting policies and calculations are concerned, the Profit Estimate has been properly compiled in accordance with the bases adopted by the directors as set out in Appendix III of the Prospectus and is presented on a basis consistent in all material respects with the accounting policies normally adopted by the Group as set out in our accountant’s report dated February 19, 2021, the text of which is set out in Appendix I of the Prospectus.

Yours faithfully,

**PricewaterhouseCoopers**  
Certified Public Accountants  
Hong Kong

## (C) LETTER FROM THE JOINT SPONSORS

Morgan Stanley

CREDIT SUISSE 

The Board of Directors

SciClone Pharmaceuticals (Holdings) Limited 賽生藥業控股有限公司

February 19, 2021

Dear Sirs,

We refer to the profit estimate of the consolidated profit attributable to owners of SciClone Pharmaceuticals (Holdings) Limited (the “**Company**”) for the year ended December 31, 2020 (the “**Profit Estimate**”) set forth in the section headed “Financial Information — Profit estimate for the year ended December 31, 2020” in the prospectus of the Company dated February 19, 2021 (the “**Prospectus**”).

The Profit Estimate, for which you as the Directors of the Company are solely responsible for, has been prepared by the Directors of the Company based on the audited consolidated results of the Company and its subsidiaries (collectively, the “**Group**”) for the nine months ended September 30, 2020 and the unaudited consolidated results based on the management accounts of the Group for the three months ended December 31, 2020.

We have discussed with you the bases and assumptions made by the Directors of the Company as set forth in Appendix III to the Prospectus, upon which the Profit Estimate has been made. We have also considered, and relied upon, the letter dated February 19, 2021 addressed to you and us from PricewaterhouseCoopers, the reporting accountant of the Company (the “**Reporting Accountant**”), regarding the accounting policies and calculations upon which the Profit Estimate has been made.

On the basis of the information comprising the Profit Estimate and on the basis of the accounting policies and calculations adopted by you and reviewed by the Reporting Accountant, we are of the opinion that the Profit Estimate, for which you as the Directors of the Company are solely responsible for, has been made after due and careful enquiry.

Yours faithfully,

For and on behalf of  
**Morgan Stanley Asia  
Limited**  
**Steven Li**  
*Executive Director*

For and on behalf of  
**China International  
Capital Corporation  
Hong Kong Securities  
Limited**  
**Long Liang**  
*Managing Director*

For and on behalf of  
**Credit Suisse (Hong Kong)  
Limited**  
**Kevin Rumjahn**  
*Managing Director*